Carla Rovirosa Martí
Research technician
Research group
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.
The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.